[96a5a0]: / output / allTrials / identified / NCT05609448_identified.json

Download this file

631 lines (631 with data), 26.1 kB

  1
  2
  3
  4
  5
  6
  7
  8
  9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
{
"info": {
"nct_id": "NCT05609448",
"official_title": "Real-time MR Imaged Treatment With Holmium Microspheres of Patients With Primary Liver Cancer; a Single Center, Interventional, Non-randomized, Feasibility Study",
"inclusion_criteria": "1. Diagnosis of hepatocellular carcinoma BCLC stage B or C\n2. At least one lesion of 10 mm or more in the longest diameter on contrast-enhanced MRI/CT\n3. Patient is eligible for TARE as determined by the tumour board (in Dutch: MDO)\n4. Patient has a life expectancy of 12 weeks or longer\n5. Patient has a WHO performance score of 0-2\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
"exclusion_criteria": "1. Extrahepatic disease that cannot be targeted during the TARE session (enlarged lymph nodes in the liver hilus are allowed)\n2. Radiation therapy, chemotherapy or major surgery within 4 weeks before treatment\n3. Serum bilirubin > 2.0 x the upper limit of normal\n4. ALAT, ASAT, alkaline phosphatase (AF) > 5x the upper limit of normal\n5. Leukocytes <4.0 * 109/L or platelet count <60 * 109/L\n6. Significant heart disease that in the opinion of the physician increases the risk of ventricular arrhythmia.\n7. Pregnancy or breast feeding\n8. Disease with increased chance of liver toxicity, such as primary biliary cirrhosis or xeroderma pigmentosum\n9. Patients ineligible to undergo MR-imaging (claustrophobia, metal implants, etc)\n10. Portal vein thrombosis of the main branch (more distal branches are allowed)\n11. Untreated, active hepatitis\n12. Body weight > 150 kg (because of maximum table load)\n13. Severe allergy for i.v. contrast (Iomeron, Dotarem and/or Primovist)\n14. Lung shunt > 30 Gy, as calculated using scout dose 166Ho SPECT/CT.\n15. Uncorrectable extrahepatic deposition of scout dose activity. Activity in the falciform ligament, portal lymph nodes or gallbladder are accepted.\n16. Unstable final catheter position due to hepatic artery anatomy, which might lead to dislocation of the catheter during transfer to the MRI.",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"line": "1. Diagnosis of hepatocellular carcinoma BCLC stage B or C",
"criterions": [
{
"exact_snippets": "Diagnosis of hepatocellular carcinoma",
"criterion": "hepatocellular carcinoma",
"requirements": [
{
"requirement_type": "diagnosis",
"expected_value": true
}
]
},
{
"exact_snippets": "BCLC stage B or C",
"criterion": "BCLC stage",
"requirements": [
{
"requirement_type": "stage",
"expected_value": [
"B",
"C"
]
}
]
}
]
},
{
"line": "2. At least one lesion of 10 mm or more in the longest diameter on contrast-enhanced MRI/CT",
"criterions": [
{
"exact_snippets": "At least one lesion of 10 mm or more in the longest diameter",
"criterion": "lesion size",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": ">=",
"value": 1,
"unit": "lesion"
}
},
{
"requirement_type": "size",
"expected_value": {
"operator": ">=",
"value": 10,
"unit": "mm"
}
}
]
},
{
"exact_snippets": "on contrast-enhanced MRI/CT",
"criterion": "imaging modality",
"requirements": [
{
"requirement_type": "type",
"expected_value": [
"contrast-enhanced MRI",
"CT"
]
}
]
}
]
},
{
"line": "3. Patient is eligible for TARE as determined by the tumour board (in Dutch: MDO)",
"criterions": [
{
"exact_snippets": "eligible for TARE as determined by the tumour board",
"criterion": "eligibility for TARE",
"requirements": [
{
"requirement_type": "determination",
"expected_value": "tumour board"
}
]
}
]
},
{
"line": "4. Patient has a life expectancy of 12 weeks or longer",
"criterions": [
{
"exact_snippets": "life expectancy of 12 weeks or longer",
"criterion": "life expectancy",
"requirements": [
{
"requirement_type": "duration",
"expected_value": {
"operator": ">=",
"value": 12,
"unit": "weeks"
}
}
]
}
]
},
{
"line": "5. Patient has a WHO performance score of 0-2",
"criterions": [
{
"exact_snippets": "WHO performance score of 0-2",
"criterion": "WHO performance score",
"requirements": [
{
"requirement_type": "range",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 0,
"unit": "N/A"
},
{
"operator": "<=",
"value": 2,
"unit": "N/A"
}
]
}
}
]
}
]
},
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "healthy"
}
]
}
]
},
{
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
]
}
]
}
],
"exclusion_lines": [
{
"line": "1. Extrahepatic disease that cannot be targeted during the TARE session (enlarged lymph nodes in the liver hilus are allowed)",
"criterions": [
{
"exact_snippets": "Extrahepatic disease that cannot be targeted during the TARE session",
"criterion": "extrahepatic disease",
"requirements": [
{
"requirement_type": "targetability",
"expected_value": false
}
]
},
{
"exact_snippets": "enlarged lymph nodes in the liver hilus are allowed",
"criterion": "enlarged lymph nodes in the liver hilus",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "2. Radiation therapy, chemotherapy or major surgery within 4 weeks before treatment",
"criterions": [
{
"exact_snippets": "Radiation therapy ... within 4 weeks before treatment",
"criterion": "radiation therapy",
"requirements": [
{
"requirement_type": "time since last treatment",
"expected_value": {
"operator": ">=",
"value": 4,
"unit": "weeks"
}
}
]
},
{
"exact_snippets": "chemotherapy ... within 4 weeks before treatment",
"criterion": "chemotherapy",
"requirements": [
{
"requirement_type": "time since last treatment",
"expected_value": {
"operator": ">=",
"value": 4,
"unit": "weeks"
}
}
]
},
{
"exact_snippets": "major surgery within 4 weeks before treatment",
"criterion": "major surgery",
"requirements": [
{
"requirement_type": "time since last treatment",
"expected_value": {
"operator": ">=",
"value": 4,
"unit": "weeks"
}
}
]
}
]
},
{
"line": "3. Serum bilirubin > 2.0 x the upper limit of normal",
"criterions": [
{
"exact_snippets": "Serum bilirubin > 2.0 x the upper limit of normal",
"criterion": "serum bilirubin",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": ">",
"value": 2.0,
"unit": "x the upper limit of normal"
}
}
]
}
]
},
{
"line": "4. ALAT, ASAT, alkaline phosphatase (AF) > 5x the upper limit of normal",
"criterions": [
{
"exact_snippets": "ALAT ... > 5x the upper limit of normal",
"criterion": "ALAT",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": ">",
"value": 5,
"unit": "x the upper limit of normal"
}
}
]
},
{
"exact_snippets": "ASAT ... > 5x the upper limit of normal",
"criterion": "ASAT",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": ">",
"value": 5,
"unit": "x the upper limit of normal"
}
}
]
},
{
"exact_snippets": "alkaline phosphatase (AF) ... > 5x the upper limit of normal",
"criterion": "alkaline phosphatase (AF)",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": ">",
"value": 5,
"unit": "x the upper limit of normal"
}
}
]
}
]
},
{
"line": "5. Leukocytes <4.0 * 109/L or platelet count <60 * 109/L",
"criterions": [
{
"exact_snippets": "Leukocytes <4.0 * 109/L",
"criterion": "leukocytes",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": "<",
"value": 4.0,
"unit": "* 10^9/L"
}
}
]
},
{
"exact_snippets": "platelet count <60 * 109/L",
"criterion": "platelet count",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": "<",
"value": 60,
"unit": "* 10^9/L"
}
}
]
}
]
},
{
"line": "6. Significant heart disease that in the opinion of the physician increases the risk of ventricular arrhythmia.",
"criterions": [
{
"exact_snippets": "Significant heart disease",
"criterion": "heart disease",
"requirements": [
{
"requirement_type": "severity",
"expected_value": "significant"
}
]
},
{
"exact_snippets": "increases the risk of ventricular arrhythmia",
"criterion": "risk of ventricular arrhythmia",
"requirements": [
{
"requirement_type": "severity",
"expected_value": "increased"
}
]
}
]
},
{
"line": "7. Pregnancy or breast feeding",
"criterions": [
{
"exact_snippets": "Pregnancy",
"criterion": "pregnancy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "breast feeding",
"criterion": "breast feeding",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "8. Disease with increased chance of liver toxicity, such as primary biliary cirrhosis or xeroderma pigmentosum",
"criterions": [
{
"exact_snippets": "Disease with increased chance of liver toxicity",
"criterion": "disease with increased chance of liver toxicity",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "primary biliary cirrhosis",
"criterion": "primary biliary cirrhosis",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "xeroderma pigmentosum",
"criterion": "xeroderma pigmentosum",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "9. Patients ineligible to undergo MR-imaging (claustrophobia, metal implants, etc)",
"criterions": [
{
"exact_snippets": "ineligible to undergo MR-imaging",
"criterion": "MR-imaging eligibility",
"requirements": [
{
"requirement_type": "eligibility",
"expected_value": true
}
]
},
{
"exact_snippets": "claustrophobia",
"criterion": "claustrophobia",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "metal implants",
"criterion": "metal implants",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "10. Portal vein thrombosis of the main branch (more distal branches are allowed)",
"criterions": [
{
"exact_snippets": "Portal vein thrombosis of the main branch",
"criterion": "portal vein thrombosis",
"requirements": [
{
"requirement_type": "location",
"expected_value": "main branch"
}
]
},
{
"exact_snippets": "more distal branches are allowed",
"criterion": "portal vein thrombosis",
"requirements": [
{
"requirement_type": "location",
"expected_value": "more distal branches"
}
]
}
]
},
{
"line": "11. Untreated, active hepatitis",
"criterions": [
{
"exact_snippets": "Untreated, active hepatitis",
"criterion": "hepatitis",
"requirements": [
{
"requirement_type": "treatment status",
"expected_value": "untreated"
},
{
"requirement_type": "activity status",
"expected_value": "active"
}
]
}
]
},
{
"line": "12. Body weight > 150 kg (because of maximum table load)",
"criterions": [
{
"exact_snippets": "Body weight > 150 kg",
"criterion": "body weight",
"requirements": [
{
"requirement_type": "weight",
"expected_value": {
"operator": ">",
"value": 150,
"unit": "kg"
}
}
]
}
]
},
{
"line": "13. Severe allergy for i.v. contrast (Iomeron, Dotarem and/or Primovist)",
"criterions": [
{
"exact_snippets": "Severe allergy for i.v. contrast (Iomeron, Dotarem and/or Primovist)",
"criterion": "allergy to i.v. contrast",
"requirements": [
{
"requirement_type": "severity",
"expected_value": "severe"
},
{
"requirement_type": "specific agents",
"expected_value": [
"Iomeron",
"Dotarem",
"Primovist"
]
}
]
}
]
},
{
"line": "14. Lung shunt > 30 Gy, as calculated using scout dose 166Ho SPECT/CT.",
"criterions": [
{
"exact_snippets": "Lung shunt > 30 Gy",
"criterion": "lung shunt",
"requirements": [
{
"requirement_type": "amount",
"expected_value": {
"operator": ">",
"value": 30,
"unit": "Gy"
}
}
]
}
]
},
{
"line": "15. Uncorrectable extrahepatic deposition of scout dose activity. Activity in the falciform ligament, portal lymph nodes or gallbladder are accepted.",
"criterions": [
{
"exact_snippets": "Uncorrectable extrahepatic deposition of scout dose activity",
"criterion": "extrahepatic deposition of scout dose activity",
"requirements": [
{
"requirement_type": "correctability",
"expected_value": false
}
]
},
{
"exact_snippets": "Activity in the falciform ligament, portal lymph nodes or gallbladder are accepted",
"criterion": "activity in specific locations",
"requirements": [
{
"requirement_type": "locations",
"expected_value": [
"falciform ligament",
"portal lymph nodes",
"gallbladder"
]
}
]
}
]
},
{
"line": "16. Unstable final catheter position due to hepatic artery anatomy, which might lead to dislocation of the catheter during transfer to the MRI.",
"criterions": [
{
"exact_snippets": "Unstable final catheter position",
"criterion": "catheter position",
"requirements": [
{
"requirement_type": "stability",
"expected_value": false
}
]
},
{
"exact_snippets": "hepatic artery anatomy",
"criterion": "hepatic artery anatomy",
"requirements": [
{
"requirement_type": "condition",
"expected_value": "unstable"
}
]
}
]
}
],
"miscellaneous_lines": [],
"failed_inclusion": [],
"failed_exclusion": [],
"failed_miscellaneous": []
}